aTyr Pharma (NASDAQ: LIFE) reported Q1 EPS of ($0.36), in-line with the analyst estimate of ($0.36).

“This has been a very difficult process and we regret the impact this business decision has on our departing employees and their families. We are grateful for the many contributions of our impacted employees and I want to sincerely thank them for all their hard work and commitment to aTyr,” commented Sanjay Shukla, M.D., M.S., President and CEO of aTyr. “Going forward, we are primarily focused on ATYR1923 and designing a future patient trial which will be influenced by data from our ongoing Phase I trial, translational activities and research related to the role of the receptor for ATYR1923.”

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.